宫颈癌年度复发风险模型指导个体化监测策略
基于国际SCCAN联盟4343例早期宫颈癌患者数据,开发并内部验证了预测无病生存的Cox模型,纳入5个预后变量并划分5个风险组。据此计算年度复发风险模型(ARRM),低危组全程年复发风险低于1%,中危组在第3、4及5年后降至1%以下,为个体化监测策略提供依据。
要点
- 5变量预后模型可区分5个风险组,5年DFS从97.5%至63.3%。
- ARRM显示低危组年复发风险始终低于1%,中危组第3年后降至1%以下。
- 全队列26%复发在随访第1年,48%在第2年,78%在第5年。
核心结论
- ARRM可基于患者风险状态和年度复发风险,为早期宫颈癌患者量身定制监测策略,且易于在国际常规临床环境中使用。
研究设计与样本
- 研究数据来自国际SCCAN联盟2007至2016年间治疗的4343例早期宫颈癌患者。
- 开发并内部验证了预测无病生存(DFS)的Cox比例风险模型,基于回归系数得出风险评分并分层。
主要发现
- 预后模型纳入5个变量:最大病理肿瘤直径、肿瘤组织学类型、分级、阳性盆腔淋巴结数目和淋巴血管间隙浸润。
- 识别出5个预后显著不同的风险组,5年DFS分别为97.5%、94.7%、85.2%和63.3%(风险递增组),最高风险组2年DFS为15.4%。
- 基于ARRM,最低风险组自随访开始年复发风险即低于1%,中危组分别在随访第3年、第4年和>5年降至1%以下。
- 全队列中26%的复发出现在随访第1年,48%在第2年,78%在第5年。
临床怎么用
- 可根据ARRM评估早期宫颈癌患者各年度的复发风险,据此调整随访频率和检查强度。
局限性
- 模型仅进行了内部验证,未提及外部验证结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Current guidelines for surveillance strategy in cervical cancer are rigid, recommending the same strategy for all survivors. The aim of this study was to develop a robust model allowing for individualised surveillance based on a patient's risk profile. METHODS: Data of 4343 early-stage patients with cervical cancer treated between 2007 and 2016 were obtained from the international SCCAN (Surveillance in Cervical Cancer) consortium. The Cox proportional hazards model predicting disease-free survival (DFS) was developed and internally validated. The risk score, derived from regression coefficients of the model, stratified the cohort into significantly distinctive risk groups. On its basis, the annual recurrence risk model (ARRM) was calculated. RESULTS: Five variables were included in the prognostic model: maximal pathologic tumour diameter; tumour histotype; grade; number of positive pelvic lymph nodes; and lymphovascular space invasion. Five risk groups significantly differing in prognosis were identified with a five-year DFS of 97.5%, 94.7%, 85.2% and 63.3% in increasing risk groups, whereas a two-year DFS in the highest risk group equalled 15.4%. Based on the ARRM, the annual recurrence risk in the lowest risk group was below 1% since the beginning of follow-up and declined below 1% at years three, four and >5 in the medium-risk groups. In the whole cohort, 26% of recurrences appeared at the first year of the follow-up, 48% by year two and 78% by year five. CONCLUSION: The ARRM represents a potent tool for tailoring the surveillance strategy in early-stage patients with cervical cancer based on the patient's risk status and respective annual recurrence risk. It can easily be used in routine clinical settings internationally.
引用
- Cibula D, Dostálek L, Jarkovsky J, et al. The annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer. Eur J Cancer. 2021. PMID: 34666213. doi:10.1016/j.ejca.2021.09.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。